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Deregulated Notch signaling has been extensively linked to T-cell acute lymphoblastic leukemia (T-ALL). Here, we show
a direct relationship between Notch3 receptor and Jagged1 ligand in human cell lines and in a mouse model of T-ALL.
We provide evidence that Notch-specific ligand Jagged1 is a new Notch3 signaling target gene. This essential event
justifies an aberrant Notch3/Jagged1 cis-expression inside the same cell. Moreover, we demonstrate in Notch3-IC–
overexpressing T lymphoma cells that Jagged1 undergoes a raft-associated constitutive processing. The proteolytic
cleavage allows the Jagged1 intracellular domain to empowerNotch signaling activity and to increase the transcriptional
activation of Jagged1 itself (autocrine effect). On theother hand, the release of the soluble Jagged1 extracellular domain
has a positive impact on activating Notch signaling in adjacent cells (paracrine effect), finally giving rise to a Notch3/
Jagged1 auto-sustaining loop that supports the survival, proliferation, and invasionof lymphomacells andcontributes to
the development and progression of Notch-dependent T-ALL. These observations are also supported by a study
conducted on a cohort of patients in which Jagged1 expression is associated to adverse prognosis.
Neoplasia (2014) 16, 1007–1017Introduction
Notch receptors and their specific ligands play a key role in the early
development of multicellular organisms and deregulated Notchsignaling can cause human diseases, including cancer [1,2]. The
mammalian Notch signaling network consists of four transmembranePrograms (2010MCLPLB), the European Union (FP7-MC-ITN 215761-NotchIT),
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transmembrane Notch ligands (Jagged1 and 2 and Delta-like 1, 3,
and 4) [3,4]. Under physiological conditions, the activation of Notch
signaling requires the binding “in trans” between Notch receptors,
expressed on the surface of signal-receiving cells, with Notch ligands,
expressed on the surface of adjacent signal-sending cells. Such an
interaction renders Notch susceptible to proteolytic processing that
ends in the release of its intracellular domain (Notch-IC) [5,6].
Notch-IC moves into the nucleus, where it directly interacts with the
Recombination signal Binding Protein for immunoglobulin kappa J
region (RBP-Jκ) transcription factor [7,8] and recruits co-activators to
transcriptionally activate several downstream effectors, such as the
ubiquitous hairy and enhancer of split [8] and the T cell precursor–
specific pTalpha (pTα) [9].
Like Notch, Jagged1, after binding, becomes a substrate for
proteolysis by a member of A Disintegrin And Metalloprotease
(ADAM) family. The ADAM17 activity allows the shedding of the
ectodomain fragment (sJag1-ECD) and generates a membrane-tethered
intracellular domain (Jag1-TMICD) [10–12]. Then, the Jag1-TMICD
fragment undergoes an intramembrane cleavage mediated by pre-
senilin/γ-secretase complex activity that releases a soluble intracellular
fragment (Jag1-ICD) [11], which moves into the nucleus [13].
Intriguingly, it has been suggested that Jag1-ICD plays a role in
controlling the expression of both Jagged1 itself and Notch3 mRNAs
and contribute to transformation of E1A-immortalized baby rat kidney
(RKE) cells, although through an unknownmolecularmechanism [13].
Consistent with this original observation, it has been reported that the
overexpression of Jagged1 protein was associated with a poor prognosis
in several human tumors [14–16]. Moreover, it has been suggested that
Jagged1/Notch3 co-expression could be important for the malignant
transformation [17–21].
In this report, we show the existence of a direct relationship
between Notch3 receptor and Jagged1 ligand in T cell acute
lymphoblastic leukemia (T-ALL) context. Our data first suggest that
Jagged1 is a novel Notch3 target gene and the enforced expression of
Notch3-IC is able to determine a cell membrane lipid raft–associated
constitutive processing of Jagged1. Second, we show a Notch3/
Jagged1 cis-interaction within the same cell, which results in the
autocrine reinforcement of Notch3 signaling. Finally, the shedding of
sJag1-ECD trigged by the ADAM17 activity ends in the paracrine
amplification of Notch signaling in adjacent cells. These findings
suggest that the dysregulated expression and processing of Jagged1
protein, sustained by Notch3, takes part in a multistep oncogenic
process, playing a role in controlling cell growth, apoptosis, and
migration, favoring tumor aggressiveness and progression.Materials and Methods
Mice
The generation and typing of Notch3-IC transgenic (N3-ICtg)
mouse have been described elsewhere [22]. The studies involving
animals have been conducted following the Italian National
Guidelines for Animal Care, established in DL No. 26, 2014 and
in accord with Directive 2010/63/UE.
Cell Culture and Treatments
HEK-293T, preT 2017 [23], SCB29 [24], N3-232T [22], KE37,
Molt3, Dnd4.1, Cem, Jurkat, P12-Ichikawa, SIL-ALL, and Kopkt
[25,26] were maintained as described elsewhere. An opportuneamount of cells was treated with different compounds: 10 mM
methyl-β-cyclodextrin (MβCD; Sigma-Aldrich, St. Louis, MO, USA)
for 30 minutes at 37°C before harvesting, 10 μM TAPI-2 (Peptides
International, Louisville, KY, USA), or 5 μM γ-secretase inhibitor I
(GSI-I; Calbiochem, Darmstadt, Germany), for the times indicated
in the figures. The SCB29 cells were grown in N3-232T cell
culture-conditioned medium (CCM) in the presence or absence of
both 10 μM GSI-I for 12 hours before processing and 10 μg/ml
anti-CD339 Jagged1 neutralizing antibody (eBioscience, San
Diego, CA, USA).
Plasmids
The two putative Jagged1 promoter regions were amplified by
polymerase chain reaction (PCR) from N3-232T genomic DNA
(ENSMUST00000028735), using specific primers containing MluI
and BglII restriction sites. The following primers were used to amplify
murine pJ1pro−3794/−2156 and murine pJ1pro–1351/−237, respectively:
5′-GCGCACGCGTACCATCTCCTTCTCCCATCTCCT-3′ and
5′- GCGCAGATCT ACCGGACTTCTT ACCTGCA TCTC-3′;
5′- GCGCACGCGT ACCA TCACCT ATCTCAGGTGGTT AA
AA TG-3′ and 5′-GCGCAGATCTACCGATCAGTGTCCCGGG
GAG-3′. Briefly, both DNA fragments were amplified for 30 cycles
and then purified by means of a Qiagen quick spin column. The
DNA fragments amplified were digested using BglII (New England
BioLabs, Ipswich, MA, USA) and MluI (New England BioLabs)
enzymes and ligated into pGL3 Basic Vector (Promega, Madison,WI).
Cloned PCR products were verified by sequencing. The following
plasmids were kindly provided by A.J. Capobianco: pBABE-SerTMIC
(Jagged1-TMICD) and pBABE-Jagged1 WT (Jagged1-FL). Further-
more, the expression vectors for CMV-Notch3-IC, CMV-Notch1-IC,
RBP-Jκ, Flag-MAML1, and pTα-luc were previously described [22,27].
Cell Transfection and Luciferase Assay
Transient transfection of preT 2017 and HEK-293T cell lines with
pTα-luc, pJ1pro−3794/−2156, or pJ1pro−1351/−237 reporter plasmids
with different combinations of the expression vectors, described above,
was performed by using the Lipofectamine 2000 kit (Life Technologies,
Carlsbad, CA, USA, Invitrogen), according to the manufacturer's
instructions. pcDNA3 has been used as a control empty vector. Renilla
luciferase reporter vector, pTK-Renilla-Luc, was also incorporated into
each transfection for normalization (Promega). For luciferase assay,
Firefly- and pRL-TK–derived Renilla luciferase activities weremeasured
in each sample with the Dual Luciferase Assay System (Promega) on
GloMax (Promega).
RNA Interference Analysis
The target sequences of small interfering RNA (siRNA) oligonucle-
otide probes for human Notch3 were purchased from Dharmacon, GE
Healthcare, Lafayette, CO, USA, Thermo Fisher Scientific, Waltham,
MA USA (L-011093-00-0005). Human Molt3, P12-Ichikawa, SIL-
ALL, and Kopkt cell lines at subconfluence were transfected with the
indicated siRNA using the Neon Transfection System (Invitrogen).
Protein Extract Preparation, Immunoprecipitation, and
Immunoblot Analysis
Protein extract preparation, immunoprecipitation assay, and sucrose
gradient for raft isolation were performed as described elsewhere [28].
For immunoblot analysis, protein extracts were separated by NuPage
4% to 12% Bis-Tris gels (Life Technologies, Invitrogen), transferred to
a nitrocellulose membrane, and probed with the following primary
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(Santa Cruz Biotechnology), anti-Notch3 M20 (Santa Cruz
Biotechnology), anti–lamin B (Santa Cruz Biotechnology), anti-
HA (Santa Cruz Biotechnology, Dallas, TX, USA), anti-Jagged1
C20 (Santa Cruz Biotechnology), anti–β-actin (Sigma-Aldrich),
anti–c-Myc (Sigma-Aldrich) and anti-Flag (Sigma-Aldrich), anti-
ADAM17 (Abcam, Cambridge, MA, USA), anti-Jagged1 N-
terminal (Abcam), and anti–RBP-Jκ (Cell Signaling Technology,
Beverly, MA, USA). Bound antibodies were detected with
enhanced chemiluminescence (ECL kit, Amersham, GE Health-
care, Lafayette, CO, USA).
Extracellularly Shed Protein Preparation
To detect the extracellular soluble Jagged1 (sJag1-ECD) protein into
the mice serum, an appropriate amount of whole blood was collected in
a Vacutainer covered test tube (Becton Dickinson, BD, San Jose, CA,
USA). After collection, the blood is allowed to clot by leaving it at room
temperature for 30 minutes. Then, the blood was centrifuged at 300g
for 15 minutes and the resulting supernatant fraction was transferred in
a clean polypropylene tube using a Pasteur pipette. Conversely, to
identify sJag1-ECD in N3-232T CCM, an amount of CCM was
collected in a polypropylene tube and centrifuged at 200g for 10minutes.
For immunoblot analysis, soluble proteins were separated byNuPage 4%
to 12% Bis-Tris gels (Life Technologies, Invitrogen), transferred to a
nitrocellulose membrane, and probed with anti-Jagged1 N-terminal
(Abcam) antibody.
RNA Analysis, Reverse Transcription–PCR, and Quantitative
Real-Time Reverse Transcription–PCR
Total RNA was extracted from unfractioned T lymphocytes (both
from thymi and splenocytes), from untransfected preT 2017 [23] and
N3-232T cell lines [22] using MiniKit RNA Extraction (Qiagen,
Germantown, MD, USA) according to the manufacturer's instruc-
tions. A 1-μg portion of RNA was processed for reverse transcription
(RT)–PCR as previously described [27]. Quantitative real-time RT-
PCR (qRT-PCR) analysis of pTα, Jagged1, and HPRT mRNA was
performed on cDNA using TaqMan gene expression assays according
to the manufacturer's instructions (Applied Biosystems, Life
Technologies Brand, Carlsbad, CA, USA) and using the ABI Prism
7900HT (Applied Biosystems). mRNA quantification was expressed,
in arbitrary units, as the ratio of the sample quantity to the calibrator
or to the mean values of control samples.Immunofluorescence Staining
To detect Jagged1 and Notch3, N3-232T cells were plated onto
polylysine-coated Lab-Tek chamber slides. Briefly, cells were fixed with
4% paraformaldehyde for 20 minutes at room temperature, incubated
first with 1 M glycine for 15 minutes and then with 0.2% Triton X-100
and successively in blocking solution (1% BSA). Cells were stained with
primary antibodies diluted in blocking solution for 1 hour at room
temperature; after three washes, the cells were incubated with secondary
antibodies. Primary antibodies were goat anti-Jagged1 C20 (Santa
Cruz Biotechnology) and rabbit anti-Notch3 M-134 (Santa Cruz
Biotechnology). 594- and 488-conjugated anti-rabbit and anti-
goat secondary antibodies were purchased from Molecular Probes
(Life Technologies, Invitrogen). Nuclei were counterstained with
Hoechst reagent. Images were acquired with Carl Zeiss microscope
(Axio Observer Z1) using Apotome technology and AxioVision
Digital Image Processing Software.Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as described
earlier [27]. Briefly, protein complexes were cross-linked toDNA in living
nuclei of N3-232T cells. In total, 5 μg of antibody (anti–RBP-Jκ sc-
28713X or rabbit IgG sc-2027; Santa Cruz Biotechnology) was added to
each aliquot of chromatin. Immunoprecipitated DNAwas eluted and
analyzed by PCR with primer set 5′GTTAGGTTCTTTTCAGGCCG-3′
and 5′CTGCTGGGAACTTTTGAAAAAC-3.
Cell Growth, Apoptosis, and Invasion Assay
After treatment with TAPI-2 or vehicle, N3-232T andMolt3 cells
were harvested and plated in an opportune amount for each assay. To
analyze the cell growth rate, 5000 cells per well were plated onto a 96-
well plate. The MTT solution (Sigma-Aldrich) was added to each
well according to the manufacturer's instructions and dissolved by
adding DMSO. Spectrophotometric absorbance at a wavelength of
570 nm was determined by the plate reader GloMax-Multi
Detection System (Promega).
To check apoptosis, N3-232T cells were resuspended in 1× binding
buffer (BD Pharmigen) at a final concentration of 106 cells/ml and
Allophycocyanin (APC)–Annexin V (BD Pharmigen) was added at the
opportune concentration, following the manufacturer's instructions.
The analysis was performed by using a FACS-Calibur cytometer (BD
Biosciences, San Jose, CA), within 1 hour. To test the invasion ability of
the Jurkat cell line after TAPI-2 treatment, 300,000 cells per well were
plated in pre-warmed Matrigel Invasion Chamber (Corning,
Tewksbury, MA, USA) and allowed to move into the lower layer
characterized by the presence of a chemoattractant such as 5% FBS, in
tissue culture medium. After 22 hours, the %invasion was measured as
the percentage of the rate between the mean of cells invading through
the Matrigel insert membrane and the mean of cells migrating through
the control insert membrane, following the manufacturer's instruction.
Statistical Analysis
Results were reported as the mean ± SD. A Student's t test for
paired samples was used to assess differences among groups. For
multiple comparisons of groups, one-way analysis of variance was
used. A P value b .05 was considered statistically significant (*P b .05,
**P b .01, and ***P b .001.Results
Jagged1 Constitutive Processing Occurs in Notch3-IC–
Overexpressing Lymphoma Cells
To study the putative relationship between Notch3 and Jagged1
(Jag1) in T-ALL, we first investigated Jag1 expression in N3-232T
lymphoma cells, a cell line established from a lymphoma-bearing
Notch3-IC transgenic (N3-ICtg) mouse, which we previously
demonstrated to represent a mouse model of human T-ALL [22,29].
We show that N3-232T cells display a significantly high expression of
Jag1 full-length protein (Jag1-FL), when compared to the preT 2017
cell line [23], T-lymphoma cells phenotypically comparable to N3-
232T cells, but expressing onlyNotch3 full-length and not theNotch3-
IC and which does not express at all Jag1 (Figure 1A).
Notably, preT 2017 cells express instead the constitutively active
Notch1-IC, as revealed by immunoreactivity to anti-Notch1 Val1744
(N1-Val1744) antibody (Figure 1A). Moreover, double immunoflu-
orescence staining shows that in N3-232T cells the expression of Jag1
and Notch3 takes place within the same cell, a phenomenon defined
Figure 1. Cis-expression and interaction of Jagged1 and Notch3 in N3-232T lymphoma cells. (A). Jagged1, Notch3, and Notch1
expression was determined in WCEs by immunoblot analysis using specific antibodies raised against the C-terminal region of the
analyzed proteins and able to detect their full-length and/or the processed forms. To reveal the activated form of Notch1, an anti-Notch1
Val1744 antibody was used. Anti–β-actin was used as a loading control (B) Jagged1 (green) and Notch3 (red) cis-expression (merge) was
analyzed by double immunofluorescence staining. Magnification: ×40. (C) sJag1-ECD sheds in N3-232T CCM revealed by immunoblot
analysis. (D–F) sJag1-ECD triggers Notch signaling on neighboring cells. (D) SCB29 cells were cultured with N3-232T CCM for the
indicated time, in the presence of vehicle alone (DMSO) or GSI-I. The expression of cleaved Notch3-IC (N3-IC) and activated Notch1 (N1-
Val1744) was analyzed by Western blot. (E and F) qRT-PCR analysis of pTα and Jag1 target genes in the presence of DMSO or GSI-I in
SCB29 cells grown in N3-232T CCM. The data are represented as fold of activation with respect to starting time. The graph bars display
the means ± SD of three independent experiments, made in triplicate. ***P b .001. (G) Expression levels of pTαmRNA evaluated by qRT-
PCR in SCB29 cultured in N3-232T CCM in the presence of control IgG or JAG1 neutralizing antibody (anti-Jag1). The level of pTαmRNA
from SCB29 cells cultured in CCM plus IgG was set as 100%. Mean values ± SD are shown and they were obtained from three
independent experiments, each in triplicate. *P b .05. (H) N3-232T WCEs were subjected to immunoprecipitation with anti-Jagged1
antibody and revealed in Western blot (WB) with anti-Notch3. Heavy chain IgGs (IgG H) are used as a loading control. (I) Raft (R) and non-
raft (NR) fractions from N3-232T cells were analyzed in immunoblot assays to detect the localization of Jag1-FL, Jag1-TMICD, Jag1-ICD,
pro-ADAM17, and mature ADAM17. (J) R and NR fractions derived from MβCD-treated and untreated (DMSO) N3-232T cells were used
for immunoblot assay with anti-Jagged1 antibody. Anti-616 p56lck and anti–α-tubulin were used as fraction markers; anti–β-actin was
used as a loading control. All data are representative of at least three independent experiments, each in triplicate.
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products of Jag1 processing, represented by the soluble intracellular
fragment (Jag1-ICD; Figure 1A) and by the extracellular fragment
(sJag1-ECD), shed into the CCM (Figure 1C). Interestingly, whole-
cell extracts (WCEs) from N3-ICtg thymocytes and splenocytes not
only show a high expression of Jag1-FL (Figure SS1A, upper panel) but
also a Jag1 constitutive processing, represented by the presence of the
soluble Jag1-ICD (Figure SS1A, middle panel) and the appearance of
sJag1-ECD in the blood serum of mice (Figure SS1B). Furthermore,
consistently with the notion that Jag1 is a substrate of the catalytic
activity of ADAM17, Figure SS1C shows that N3-ICtg thymocytesdisplay the expression of the ADAM17 active form, while wild-type
thymocytes only express the pro-ADAM immature form.
Interestingly, we observed that sJag1-ECD is able to trigger Notch
signaling in adjacent cells. Indeed, when we cultured SCB29 lymphoid
cells [24], we previously demonstrated to bear a functional Notch3
receptor [28] and which constitutively express activated Notch1
(Figure 1D), in the presence of theCCMofN3-232T cells, we observed
a progressive increase of both cleaved Notch3-IC and activated Notch1
(Figure 1D). The addition of GSI-I completely abrogates the expression
of Notch3-IC and activated Notch1 (Figure 1D), further validating the
hypothesis that sJag1-ECD, present in N3-232T CCM, is able to
Figure 2. Jag1-ICD interacts with and empowers the Notch3-driven transcriptional complex. (A) Extracts from non-nuclear (NN) and
nuclear (N) fractions were probed with anti-Jag1 antibody. Anti–lamin B and anti–α-tubulin were used as fraction controls. (B) WCEs from
HEK-293T cells co-transfected with different combinations of Notch3-IC-HA, RBP-Jκ, MAML1-Flag, and Jag1-TMICD-Myc expression
vectors were immunoprecipitated with anti–c-Myc and immunoblotted with antibodies as labeled. (C and D) Luciferase assay on preT
2017 cells co-transfected with pTα-luc and several combinations of plasmids encoding for MAML1, RBP-Jκ, Jag1-TMICD, and Notch3-IC
or Notch1-IC. All luciferase data are graphed as fold of activation with respect to pcDNA3 negative control. The bars represent themean of
three independent experiments ± SD, all made in triplicate; ***P b .001.
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of such activation, we observed a significant increase ofmRNA expression
levels of endogenous pTα (Figure 1E), which is rescued upon addition of
GSI-I (Figure 1E). To further confirm the specific role of sJag1-ECD shed
into CCM,we used a Jag1 neutralizing antibody (anti-Jag1) that is able to
counteract the effects of the sJagged1-ECD ligand. Figure 1G shows that
the addition of anti-Jag1 in N3-232T CCM is able to induce a 25%
decrease of pTα transcript levels with respect to the control, suggesting
that the positive effects on Notch signaling are mediated by the Jagged1
ligand. Notably, we also observed that sJag1-ECD–dependent activation
of Notch signaling results in increased expression of Jagged1 mRNA,
which is rescued by GSI treatment (Figure 1F).
To determine whether Notch3 and Jag1 could also interact with each
other, within the same cell, we performed co-immunoprecipitation
experiments using specific antibodies recognizing carboxyl-terminal
(C-terminal) region of Notch3 and Jag1 proteins. Figure 1H shows that
inWCE theC-terminal regions of the endogenous Jag1 andNotch3-IC
interact with each other.
Jagged1 Constitutive Processing Is a Lipid Raft–Associated Event
We have recently shown that Notch3 is constitutively recruited to
lipid raft in N3-232T lymphoma cells suggesting a possible role of
Notch3 in triggering and/or sustaining thymocyte activation [28].Given the observations above, we hypothesized that Jag1 may also be
recruited to lipid rafts in N3-232T cells. Figure 1I shows that Jag1-FL
and Jag1 transmembrane domain (Jag1-TMICD) are constitutively
recruited to lipid raft microdomains, whereas Jag1-ICD is detected
only in the non-raft fraction. Membrane raft microdomain integrity
depends on the presence of cholesterol and MβCD, which removes
cholesterol from the plasma membrane, disrupting the rafts. Figure 1J
shows that after MβCD treatment we cannot appreciate anymore the
release of the Jag1-ICD signaling fragment in the non-raft fraction,
suggesting a possible blockade of Jag1-FL processing. Anti-p56LCK and
anti–α-tubulin immunoblot analyses were, respectively, used as
controls for Raft (R) and non-Raft (NR) compartments (Figure 1,
I–J). ADAM17metalloprotease is mainly responsible for the cleavage of
Jag1 that allows the release of sJag1-ECD and that represents an
obligatory step before the cleavage by the presenilin/γ-secretase
complex [11]. It is known that ADAM proteins are synthesized as
inactive zymogens that are proteolytically processed to the catalytically
active forms [30]. We thus analyzed the expression of ADAM17 in
N3-232T lipid rafts and we observed a significant recruitment of its
80-kDa active form in such microdomains (Figure 1I).
Together, these observations strongly suggest that lipid raft
platform plays a functional role in triggering the ADAM17-mediated
Jag1 processing in N3-232T lymphoma cells.
Figure 3. Jagged1 is a Notch3-signaling target gene. (A) Schematic representation of murine Jagged1 putative promoter sequence. The
genomic DNA region of Jagged1 promoter ranging between −1351 and−237 bp upstream the start site (pJ1pro−1351/−237) was cloned
into pGL3 Basic luciferase vectors as described in the Materials and Methods section. (B) Activation of the Jagged1 promoter constructs
by Notch3 signaling. HEK-293T cells were co-transfected with a luciferase reporter construct containing pJ1pro−1351/−237 and Notch3
transcriptional activator complex (Notch3-IC + RBP-Jκ + MAML1). (C) ChIP assay in N3-232T cells using anti–RBP-Jκ or anti-Notch3
antibodies or IgG as control. Immunoprecipitated DNA was analyzed by PCR using a primer set that amplifies the CSL/RBP-Jκ consensus
binding site spanning between −997 and −991 bp on pJ1pro−1351/−237 promoter. (D) preT cells were transfected with Notch3-IC
expression vector and Jag1 mRNA was analysed by RT-PCR. Anti–β-actin was used as a loading control. (E) preT 2017 cells were
transfected with pJ1pro−1351/−237-luc and Notch3-IC, MAML1, and RBP-Jκ, with or without Jag1-TMICD expression vectors. All data
presented were collected from three independent experiments, each made in triplicate. The luciferase graph bars show the means ± SD
and analyzed as fold of activation with respect to pcDNA3 empty control. ***P b .001; *P b .05.
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Driven Transcriptional Complex
To address the function of different Jag1 fragments in lymphoma
cells, we have first studied their respective subcellular localization. We
observed that Jag1-FL and Jag1-TMICD are specifically located in
the non-nuclear fraction, while Jag1-ICD is able to move into the
nucleus (Figure 2A). Furthermore, co-immunoprecipitation assays
using HEK-293T cells, co-transfected with Notch3-IC–, RBP-Jκ–,
MAML1-, and Jag1-TMICD–expressing vectors, show that Jag1 is
able to interact with the transcription factor RBP-Jκ and to take part
in the Notch3-IC transcriptional complex (Figure 2B). To investigate
whether the released Jag1-ICD was able to influence Notch3-
dependent transcription, we first monitored the ability of Jag1-ICD
to modulate the transcription of the pre-TCRα chain (pTα),
which we have previously shown to be directly regulated by
Notch3 [9] and to sustain the leukemogenesis process [29]. A
luciferase assay performed in preT 2017 cells with the pTα
promoter as a luciferase reporter (pTα-luc) shows that the addition
of Jag1-TMICD to the Notch3-IC–driven transcriptional com-
plex gives rise to a two-fold increase in transcriptional activity of
the pTα promoter (Figure 2C).
Together, these results suggest that Jag1-ICD, by binding to
RBP-Jk, positively cooperate with the Notch3-driven transcrip-
tional complex, empowering its transcriptional activity. Intrigu-ingly, it has been previously shown that Jag1-ICD is able to
directly interact with Notch1 and such an interaction prevents
the formation of a Notch1-driven transcriptional complex, en-
hancing the degradation of Notch1-IC, by the FBXW7 ligase
[31]. In keeping with this, we observed that the addition of Jag1-
ICD significantly reduces Notch1 transcriptional activity in the
pTα-luc (Figure 2D).
Jagged1 Is a Transcriptional Target of Notch3 and Contributes
to Its Own Transcriptional Activation
The observations reported above allowed us to speculate that the
increased expression and processing activation of Jag1 could be the result
of the constitutive activation of Notch3. To this purpose, we investigated
the ability of Notch3 to induce the activation of the Jagged1 promoter.
We identified through the Genomatix Software two different genomic
DNA fragments putatively matching the promoter sequence of Jagged1:
pJ1pro−3794/−2156 and pJ1pro−1351/−237, respectively, characterized by
the presence of two RBP-Jκ binding sites (Figure SS2A) or one RBP-Jκ
binding site (Figure 3A).
Luciferase assays in HEK cells demonstrated that the enforced
expression of the Notch3-IC–driven transcriptional complex results in
an eight-fold induction of the pJ1pro−1351/−237 luciferase reporter
construct (pJ1pro−1351/−237-luc; Figure 3B), while it was not able to
increase the transcriptional activity of the pJ1pro−3794/−2156 (Figure
Figure 4. Relationship between Notch3 and Jag1 in human T-ALL cell lines. (A) WCEs from KE37, Molt3, Dnd4.1, Cem, Jurkat, P12-
Ichikawa, SIL-ALL, and Kopkt cell lines were analyzed by immunoblot analysis with anti-Notch3, anti-Notch1-Val1744, and anti-Jagged1
antibodies, as labeled. Anti–β-actin was used as a loading control. (B) mRNA derived from the same human T-ALL cell lines was analyzed
by qRT-PCR using a primer set specific for Jagged1. The data are analyzed as fold of activation with respect to KE37 negative control. The
graph bars display the means ± SD of three similar experiments, each in triplicate. (C) Immunoblot WCE from Molt3, P12-Ichikawa, SIL-
ALL, and Kopkt cells after silencing of Notch3 (Notch3 siRNA) compared to the control (CTR siRNA). Anti–β-actin was used as a loading
control. (D) qRT-PCR was used to determine the effects of Notch3 knockdown on Jagged1 target gene expression in Notch3-silenced
cells after 48 hours. The graph bars display the means ± SD of at least three independent experiments, analyzed as fold of activation with
respect to scramble control. **P b .01.
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RBP-Jκ and Notch3-IC constitutively bind the canonical RBP-Jk
binding site, spanning between −997 and −991 bp in the Jagged1
promoter, indicating that Jag1 is a Notch3 target gene (Figure 3C).
Moreover, Figure 3D shows that Notch3-IC transient transfection is
able to induce the increased expression of endogenous Jag1 in preT
2017 cells.
It has been previously suggested that Jag1 is able to transcriptionally
activate itself [13]. To see whether Jag1-ICD was also able to cooperate
with Notch3-IC to drive the activation of its own promoter, we co-
transfected preT 2017 cells with the pJ1pro−1351/−237-luc and Notch3-
IC, RBP-Jκ, and MAML1 expression plasmids in the presence or
absence of Jag1-TMICD. Figure 3E confirms that the Notch3-IC–
driven transcriptional complex increases the luciferase activity of
Jagged1 promoter, and as we hypothesized, the addition of Jag1-
TMICD further increases the activation of its own promoter.
Altogether our data demonstrate, for the first time, the ability ofNotch3 to regulate the transcription of its own ligand Jagged1 in a T
cell precursor context and that Jag1-ICD, in turn, is able to
strengthen the activity of Notch3-driven transcriptional complex in
triggering its own transcription.Jagged1 Expression Is Regulated by Notch3 Activity in Human
T-ALL Cell Lines and Its Processing Regulates T-ALL Cell
Survival, Proliferation, and Invasion
To assess the possible relevance of Notch3 and Jagged1
relationship in human T-ALL, we first analyzed the expression of
Jagged1 and Notch3-IC in several human T-ALL cell lines. Figure 4A
shows that all of the T-ALL cell lines analyzed express not only high
levels of activated Notch1-IC (N1-Val1744), reflecting an aberrant
activation of the Notch pathway, but also the cleaved form of Notch3
(except for KE37). Intriguingly, the presence of a cleaved Notch3-IC
correlates with the expression of Jag1-FL protein at different levels in all
of the human T-ALL cell lines analyzed, while most of them (Molt3,
Figure 5. Inhibition of Jag1 processing impairsmouse and human lymphoma cell proliferation, apoptosis, and invasiveness. (A)WCEs of N3-
232T cells treated with TAPI-2 or vehicle alone (EtOH) were immunoblotted with anti-Jag1 antibody. Anti–β-actin was used as a loading
control. (B and C) The TAPI-2 effect on growth was tested by theMTT assay, whereas apoptosis was measured by the analysis of Annexin V
staining (Annexin V+, gray bars; Annexin V−, dark bars). (D) Molt3, Kopkt, and Jurkat cell lines were treated with TAPI-2 or EtOH and the
effect on cell growthwas tested by theMTT assay. (E) The Jurkat cell line treatedwith TAPI-2 or EtOHwas used in invasionMatrigel assay. All
data presented were collected from three independent experiments. The graph bars display the means ± SD, analyzed as fold of activation
with respect to EtOH negative control. ***P b .001; **P b .01; *P b .05. (F) The graph represents gene expression profiling (GEP) data for the
expression of probe set 216268_s_at (U133 2.0 plus array; Affymetrix) representing the Jagged1 gene in a cohort of 76 pediatric T-ALL
patients. Patients were stratified in three final risk groups based on Minimal Residual Disease (MRD) levels, response to the first week of
steroids, and resistance to induction therapy. Each dot corresponds to one patient and the expression value of Jagged1 is given in log2 scale
after normalizing GEP data with justRMA algorithm normalization. JustRMA is an algorithm fulfilling two steps, namely, background
adjustment of all the probe sets present on theGeneChip and quantile normalization tomake the values of all theGeneChips comparable. The
X-axis represents patient stratification according to final risk groups, and the Y-axis represents Jagged1 gene expression level.
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release of Jag1-IC (Figure 4A). The expression levels of Jagged1 mRNA
in different cell lines, assayed by qRT-PCR, are represented in
Figure 4B. Altogether, these observations allow us to assume a direct
correlation between Notch signaling activation and Jagged1 ligand
expression in human T-ALL cell lines. Moreover, we observed that
Notch3 silencing in Molt3, P12-Ichikawa, SIL-ALL, and Kopkt cells,
confirmed by Western blot analysis (Figure 4C), results in the
significant decrease of Jagged1 transcript expression (Figure 4D),
suggesting a possible direct correlation between Notch3 and Jagged1.
Then, to finally ascertain whether Jag1 cleavage may have an impact on
lymphoma cell survival, we used the TAPI-2 compound to inhibit
ADAM17 activity [27]. We observed that TAPI-2 treatment abrogates
the cleavage of endogenous Jag1 in N3-232T cells (Figure 5A) and is
able to induce a 50% decrease of cell growth, as determined by the
MTT assay (Figure 5B). Moreover, Figure 5C shows a sharp increase
(from 20% up to 80%) of apoptosis in TAPI-2–treated N3-232T cells.
In addition, even Molt-3, Koptk1, and Jurkat cells that display a
constitutive Jagged1 cleavage (Figure 4A), when treated with the TAPI-
2 compound, disclose a reduction of cell growth, respectively, of 40%
for Molt3 and 20% for Jurkat and Koptk1 by MTT analysis, withrespect to vehicle-treated cells (Figure 5D). Interestingly, TAPI-2
treatment was not able to induce the reduction of cell growth in KE37
T-ALL cells, which do not express Jagged1 (Figure WS3). Notably, the
block of Jagged1 cleavage obtained by TAPI-2 treatment strongly
reduced Jurkat cell migration (55%), measured in Matrigel invasion
assay (Figure 5E). Together, these data indicate that a deregulated
expression and an uncontrolled processing of Jagged1 are involved in
lymphoma cell proliferation and migration/invasion, suggesting a
potential role of Jagged1 in malignant tumor progression in T-ALL.
Analyses of gene expression in a cohort of 76 pediatric T-ALL patients
revealed a general moderate expression of Jagged1, except for six cases.
Intriguingly, these six patients with a higher Jagged1 expression were
stratified in the medium and high final risk groups.
Discussion
The data presented here indicate that a direct relationship exists
between Notch3 and its ligand Jagged1, and such a relationship could
be a new puzzle’s piece to unravel the molecular mechanisms that
sustain the development and progression of T-ALL.
We first demonstrate that Jagged1 is a Notch3 target gene in
lymphoma cells from a mouse model of T-ALL and in human T-ALL
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Figure 6. Schematic representation of the reciprocal auto-sustaining loop between Jagged1 ligand and Notch3 receptor in T-ALL. (A) The
Jagged-1–triggered transactivation induces cleavage of Notch, by sequential activation of ADAM10/TACE and γ-secretase, to generate
Notch-IC. In a T ALL cell context, a Notch3-IC–driven transcriptional complex activates the Jagged1 target gene, by constitutively binding
the canonical RBP-Jκ binding site spanning between −997 and −991 bp in the Jagged1 promoter. (B) The constitutive expression of
Notch3 intracellular domain in thymocytes and lymphoma cells from N3-ICtg mice determines a Notch3/Jagged1 cis-expression within
the same cell and a constitutive raft-dependent Jagged1 processing, whose result is the empowering of Notch3 signaling. The Jagged1
intracellular domain is able to translocate into the nucleus where it is recruited specifically by the Notch3 transcriptional complex (Notch3-
IC + MAML1 + RBP-Jκ), acting as a co-activator able to sustain the activation of specific target genes, such as pTα and Jagged1 itself
(autocrine effect). On the other hand, the shedding of soluble extracellular domain of Jagged1 (sJag1-ECD) has a positive impact on
triggering Notch signaling pathway in neighboring cells (paracrine effect).
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region corresponding to Jagged1 promoter (pJag1pro−1351/−237) that
contains a canonical RBP-Jκ binding site, which is bound by RBP-Jκ
and Notch3. Our data also indicate that in both Notch3-IC–
overexpressing T lymphoma cells and in human T-ALL cell lines,
expressing a cleaved Notch3-IC, Jagged1 undergoes a constitutive
processing, revealed by the expression of the released Jag1-ICD that is
able to translocate into the nucleus and to empower Notch
transcriptional activity. We have also observed that Notch3 silencing
results in the significant decrease of Jagged1 transcript expression,
suggesting that the expression of Jagged1 can be Notch signaling
mediated in a dysregulated cell context.
Interestingly, we show that Jagged1 and the active form of
ADAM17 segregate in lipid rafts of Notch3-IC overexpressing
lymphoma cells, suggesting that Jagged1 constitutive processing is a
lipid raft microdomain–associated event. Consistently, the disrup-
tion of the rafts, by using MβCD, inhibits the release of the Jag1-ICD in a non-raft fraction. We hypothesize that such a subcellular
distribution would permit a higher degree of interaction between
Jag1 and ADAM17, which may favor the sJag1-ECD shedding.
Notably, it has been previously reported that ADAM17-mediated
cleavage of Jag1 is a lipid raft–independent event in a non–T cell
context [32], suggesting that our observation may be due to a specific
effect of the Notch3 constitutive recruitment to lipid rafts in N3-
232T lymphoma cells, which we previously reported [28].
Moreover, we present compelling evidence that the sJag1-ECD
shed in the N3-232T cell CCM is able to activate Notch signaling in
Notch receptor–bearing neighboring cells, as revealed by the
increased expression of specific Notch target genes, supporting
literature data concerning the positive effects of sJag1-ECD [33].
Noteworthy, we show that once Jag1-ICD moves to the nucleus it
can behave as a co-activator of the Notch3-IC–driven transcriptional
complex. In particular, we demonstrate that Jag1-ICD binds to the
transcription factor RBP-Jκ and is able to empower the
1016 Notch3/Jagged1 Circuity Pelullo et al. Neoplasia Vol. 16, No. 12, 2014transcriptional effect of Notch3-IC on target genes, such as pTα and
Jagged1 itself. Such a functional cooperation between Notch3 and
Jag1-ICD seems to be specific, since Kim et al. demonstrated that the
presence of Jag1-ICD accelerates the protein degradation of Notch1-
IC through FBW7 [31]. The proline, glutamic acid, serine,
threonine-rich (PEST) domain of Notch intracellular domain
(NICD) is known to regulate protein stability and is a hot spot for
mutations in primary human and mouse T-ALLs [34,35] and FBW7
binding to Notch is dependent on an intact PEST [31,36]. Thus, we
may assume that a deregulated expression of Notch ligand Jagged1,
Notch3-mediated, could synergize with PEST domain–mutated
Notch1 to potently activate the pathway. These observations allow us
to assume that a multistep oncogenic process that involve both
mutant Notch1 and unmutated Notch3 could be necessary to
regulate the expression of Jagged1 in cis, that, in turn, once cleaved, is
able to synergize with Notch3-driven transcriptional complex in the
same cell and to empower Notch signaling in trans in adjacent cells.
Jagged1 up-regulation has been recently observed in several Notch-
overexpressing human tumors, such as ovarian cancer [17], lung
cancer [18], and renal cell carcinoma [20]. Moreover, it has been
suggested that Jagged1 is able to play a role in progression and
metastasization of prostate cancer and may be a useful marker to
distinguish indolent and aggressive cancers and to predict poor
outcome in renal cell carcinoma [14,20,37]. In addition, it has been
demonstrated that the down-regulation of Jagged1 induces S phase
arrest and cell growth inhibition, regulating CDK2, cyclin A, and p27
in prostate cancer cell [38]. Finally, a role for Jagged1 in controlling
cell growth and invasion has been identified in colorectal cancer, renal
cell carcinoma, and colon cancer [20,39]. In keeping with these data,
we observe that the pharmacological inhibition of Jagged1 processing
can significantly reduce lymphoma cell proliferation and migration
and induces apoptosis of both mouse and human T-ALL cell lines.
Intriguingly, for the first time, we show that in a cohort of 76
pediatric T-ALL patients, a higher Jagged1 expression is observed in
the medium and high final risk groups.
Taken together, these data suggest that a Notch-dependent
dysregulation of Jagged1 protein takes part in a multistep oncogenic
process, playing a role in controlling not only cell growth and
apoptosis but also lymphoma cell migration, finally sustaining tumor
aggressiveness and progression.
Collectively, our results strongly suggest a new molecular mecha-
nism, which supports the hypothesis that a dysregulated Notch3
activation is able to increase the transcription of Jagged1 ligand inside
the same cell (Figure 6A) and the deregulated expression of Jagged1
is able, in turn, to empower the transcriptional activation of Notch
target genes (e.g., pTα), involved in the onset and progression of T-
ALL, and to elicit a Jagged1 auto-sustaining loop, mediated by the
transcriptional activation of Jagged1 itself (autocrine effect). On
the other hand, our data demonstrate that the constitutive release of
the sJag1-ECD has a positive impact on activating Notch signaling
in adjacent cells (paracrine effect), as suggested in the model
depicted in Figure 6B.
Finally, the significant reduction of the proliferation and the
increased apoptosis of mouse and human T-ALL cell lines, obtained
with the pharmacological block of the Jagged1 cleavage, suggest that
Jagged1 processing inhibition may be exploited, as an additional
target therapy for T-ALL.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.10.004.References
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